title: Nanomedicine-based combination of gambogic acid and retinoic acid chlorochalcone for enhanced anticancer efficacy in osteosarcoma.
abstract: In this study, gambogic acid (GA) and retinoic acid chlorochalcone (RACC) co-loaded glycol chitosan nanoparticle was successfully developed and studied for its therapeutic efficacy against osteosarcoma cancer cells. The GA/RACC loaded glycol chitosan nanoparticles (RGNP) was nanosized and exhibited a controlled release of drug in either pH 7.4 and pH 5.0. Owing to the strong positive charge on the RGNP surface, efficiency cellular uptake was observed in cancer cells. Moreover, a synergistic combination of GA and RACC were effectively suppressed the tumor growth progression. The half maximal inhibitory concentration (IC50) values in MG63 cells were 0.89μg/ml and 0.35μg/ml for GA and RGNP after 24h. The results clearly suggest the synergist effect of GA and RACC in effectively inhibiting the cancer cell proliferation. The RGNP as expected induced a remarkably higher apoptosis of cancer cells with ∼28%. Overall, combination of GA and RACC encapsulated in a nanocarrier could be an effective strategy to treat osteosarcoma. Future studies will focus on the in vivo evaluation of GA/RACC-loaded polymeric nanoparticles.
authors.affiliation: Department of Medical Oncology, Yantaishan Hospital, Yantai, Shandong, China. Electronic address: liulei2108@hotmail.com.
authors.forename: Lei
authors.initials: L
authors.lastname: Liu
authors.affiliation: Department of orthopedics, Yuhuangding Hospital, Yantai, Shandong, China.
authors.forename: Xiao-Jun
authors.initials: XJ
authors.lastname: Qi
authors.affiliation: Department of Medical Oncology, Yantaishan Hospital, Yantai, Shandong, China.
authors.forename: Zhao-Kun
authors.initials: ZK
authors.lastname: Zhong
authors.affiliation: Department of Medical Oncology, Yantaishan Hospital, Yantai, Shandong, China.
authors.forename: En-Ning
authors.initials: EN
authors.lastname: Zhang
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D003512:Cyclohexanones / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D065546:Drug Liberation; D004705:Endocytosis / Q000187:drug effects; D006801:Humans; D007700:Kinetics; D050997:Nanomedicine / Q000379:methods*; D053758:Nanoparticles / Q000737:chemistry / Q000648:ultrastructure; D012516:Osteosarcoma / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome; D014212:Tretinoin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D044004:Xanthones / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D003512:Cyclohexanones; D044004:Xanthones; C000606247:retinoic acid chlorochalcone; D014212:Tretinoin; C052659:gambogic acid
keywords: Apoptosis; Gambogic acid; Nanoparticles; Osteosarcoma; Retinoic acid chlorochalcone